Bayer and AskBio report data from Parkinson’s disease therapy trial

[Farooqji]

The bilateral infusions of AB-1005 were well tolerated, without any SAEs linked to the gene therapy or contrast agent.

AskBio Parkinson’s and MSA Scientific chair Krystof Bankiewicz said: “These early findings are encouraging and show AB-1005 to be well tolerated in this study in patients with mild to moderate Parkinson’s disease.

clinicaltrialsarena.com/new...